SG11201811564QA - Methods of treating ovarian cancer - Google Patents
Methods of treating ovarian cancerInfo
- Publication number
- SG11201811564QA SG11201811564QA SG11201811564QA SG11201811564QA SG11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- tesaro
- waltham
- suite
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 208000000260 Warts Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000010153 skin papilloma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) ill Hu omits 1E 10 01111011M 0110 011 (10) International Publication Number WO 2018/005818 Al WIPO I PCT (51) International Patent Classification: A61K 31/454 (2006.01) C12Q 1/68 (2006.01) A61K 31/4745 (2006.01) (21) International Application Number: PCT/US2017/040039 (22) International Filing Date: Published: — with international search report (Art. 21(3)) 29 June 2017 (29.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/356,461 29 June 2016 (29.06.2016) US 62/402,427 30 September 2016 (30.09.2016) US 62/470,141 10 March 2017 (10.03.2017) US (71) Applicant: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (72) Inventors: HEDLEY, Mary Lynne; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). MARTELL, Robert; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (74) Agent: SHINALL, Michael A. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(0) O 00 O 1-1 C (54) Title: METHODS OF TREATING OVARIAN CANCER (57) : The present invention provides methods of administering a PARP inhibitor to a cancer patient.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811564QA true SG11201811564QA (en) | 2019-01-30 |
Family
ID=60787744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811564QA SG11201811564QA (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20180311224A1 (en) |
| EP (2) | EP4302835A3 (en) |
| JP (2) | JP7083760B2 (en) |
| KR (2) | KR102510996B1 (en) |
| CN (1) | CN109640992A (en) |
| AU (1) | AU2017290244B2 (en) |
| BR (1) | BR112018077492A2 (en) |
| CA (1) | CA3029671C (en) |
| DK (1) | DK3478286T3 (en) |
| FI (1) | FI3478286T3 (en) |
| HR (1) | HRP20240136T1 (en) |
| IL (1) | IL263925B2 (en) |
| MA (1) | MA45563A (en) |
| MX (1) | MX2018016193A (en) |
| NZ (1) | NZ749413A (en) |
| PT (1) | PT3478286T (en) |
| RS (1) | RS65180B1 (en) |
| SG (1) | SG11201811564QA (en) |
| SI (1) | SI3478286T1 (en) |
| WO (1) | WO2018005818A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110062885A (en) | 2016-11-01 | 2019-07-26 | 安奈普泰斯生物有限公司 | For the antibody of T cell immunoglobulin and mucin 3 (TIM-3) |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| MA47208A (en) | 2017-01-09 | 2019-11-13 | Tesaro Inc | CANCER TREATMENT METHODS USING ANTI-PD-1 ANTIBODIES |
| KR20190098263A (en) | 2017-01-09 | 2019-08-21 | 테사로, 인코포레이티드 | How to Treat Cancer with Anti-TIM-3 Antibodies |
| TWI761476B (en) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | Niraparib compositions |
| CA3060715A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| JP2020519621A (en) * | 2017-05-09 | 2020-07-02 | テサロ， インコーポレイテッド | Combination therapy to treat cancer |
| MA49144A (en) | 2017-05-18 | 2020-03-25 | Tesaro Inc | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| MA50657A (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc | NIRAPARIB FORMULATIONS |
| MX2020003770A (en) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Combination therapies for treating cancer. |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| CA3090479A1 (en) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| WO2019195443A1 (en) * | 2018-04-04 | 2019-10-10 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| US20210347760A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Niraparib Salts |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| EP3857555A4 (en) | 2018-10-17 | 2022-12-21 | Tempus Labs | Data based cancer research and treatment systems and methods |
| WO2021011609A1 (en) * | 2019-07-15 | 2021-01-21 | Tesaro, Inc. | Methods of treating ovarian, fallopian tube and peritoneal cancer |
| AU2020332939A1 (en) * | 2019-08-22 | 2022-03-24 | Tempus Ai, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| EP4237090A1 (en) * | 2020-10-29 | 2023-09-06 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| KR20230114557A (en) | 2022-01-25 | 2023-08-01 | 서울대학교산학협력단 | Apparatus and method for deriving gene associated with homologous recombination deficiency, apparatus and method for generating homologous recombination deficiency determination model, apparatus and method for determining homologous recombination deficiency |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| CN115253066A (en) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | Ovarian cancer treatment system and alternating electric field generation device for ovarian cancer treatment |
| CN116092631A (en) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | Tumor treatment system combining iron death inducer and electric field |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4611444B2 (en) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN106008460B (en) | 2008-01-08 | 2022-08-12 | 默沙东公司 | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide |
| WO2011160063A2 (en) | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (en) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedures for the prediction of a response against cancer |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US20180163271A1 (en) * | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (en) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | Pyrimidine derivative, preparation method and medical application thereof |
-
2017
- 2017-06-29 SI SI201731481T patent/SI3478286T1/en unknown
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/en active Pending
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/en active
- 2017-06-29 RS RS20240163A patent/RS65180B1/en unknown
- 2017-06-29 MX MX2018016193A patent/MX2018016193A/en unknown
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/en active IP Right Grant
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 MA MA045563A patent/MA45563A/en unknown
- 2017-06-29 PT PT178212627T patent/PT3478286T/en unknown
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/en active
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en active Application Filing
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/en not_active Application Discontinuation
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/en unknown
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/en unknown
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/en active Active
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
-
2018
- 2018-05-22 US US15/986,536 patent/US20180311224A1/en active Pending
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/en active Pending
-
2022
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US20240058319A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201903842YA (en) | Combination treatment with antibody-drug conjugates and parp inhibitors | |
| SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
| SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |